GO:0034127 regulation of MyD88-independent toll-like receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034127 describes any process that modulates the frequency, rate, or extent of the MyD88-independent toll-like receptor signaling pathway, a TRIF/TRAM-dependent branch of innate immunity [1,6].
• The MyD88-independent pathway is best characterized downstream of TLR3 and TLR4 and signals through the adaptors TRIF (TICAM1) and TRAM (TICAM2) to activate IRF3/IRF7 and late NF-kB [1,6].
• IRF-7 is a master regulator of type-I interferon-dependent immune responses and is a key node whose activity is controlled by regulators of this pathway.
• Negative regulators such as signal regulatory protein alpha (SIRPA) and microRNA-7/FAM177A axis can impair or dampen MyD88-independent signaling, linking dysregulation to impaired bacterial killing [3,7].
• The pathway is evolutionarily conserved and has been reconstructed across metazoans, making it tractable for comparative and functional genomics.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect which regulators causally modulate TRIF/TRAM-dependent signaling [1,6].
Description
Toll-like receptors (TLRs) are germline-encoded sensors that initiate innate immune responses to microbial ligands. Two principal intracellular cascades operate downstream of TLRs: the MyD88-dependent pathway, which drives rapid NF-kB activation, and the MyD88-independent pathway, which depends on the adaptors TRIF and TRAM and is responsible for delayed NF-kB activation and IRF3/IRF7-dependent type-I interferon production [1,6]. GO:0034127, regulation of MyD88-independent toll-like receptor signaling pathway, is the Gene Ontology term that captures all processes modulating the frequency, rate, or extent of this TRIF/TRAM-dependent branch [1,6]. Because the MyD88-independent branch is central to antiviral and antibacterial immunity, its regulators are intensely studied. Genetic and biochemical work has shown that TRIF is indispensable for MyD88-independent TLR signaling, and that loss of TRIF abolishes IRF3 activation and interferon-beta induction downstream of TLR3 and TLR4. Subsequent studies identified IRF-7 as the master regulator of type-I interferon-dependent immune responses, placing it at the heart of the transcriptional output of this pathway. Dysregulation of MyD88-independent signaling has been linked to impaired intracellular killing of pathogens such as Burkholderia pseudomallei, to endothelial inflammatory responses to lipopolysaccharide, and to altered phagocytic actin remodeling [5,7,8]. Understanding how this pathway is regulated therefore has direct implications for infectious disease, inflammation, and host-directed therapeutics [3,6,7].
regulation of MyD88-independent toll-like receptor signaling pathway At A Glance
| GO ID | GO:0034127 |
|---|---|
| GO term | regulation of MyD88-independent toll-like receptor signaling pathway |
| Ontology | biological_process |
| Synonym | regulation of MyD88-independent TLR signaling pathway; regulation of MyD88-independent toll-like receptor signalling pathway |
| Definition | Any process that modulates the frequency, rate, or extent of MyD88-independent toll-like receptor signaling pathway. |
| Major function | Tuning TRIF/TRAM-dependent TLR signaling that drives IRF3/IRF7 activation and type-I interferon production [1,6] |
| Key adaptors | TRIF (TICAM1) and TRAM (TICAM2) [1,6] |
| Key transcription factors | IRF3 and IRF7 [1,2] |
| Representative negative regulators | SIRPA, microRNA-7/FAM177A [3,7] |
What Is GO:0034127?
GO:0034127 is a biological_process term defined as any process that modulates the frequency, rate, or extent of the MyD88-independent toll-like receptor signaling pathway. In practical terms, it covers the proteins, RNAs, and small molecules that positively or negatively tune the TRIF/TRAM-dependent branch of TLR signaling, including its activation of IRF3/IRF7 and late NF-kB, without directly describing the core signaling reactions themselves [1,6].
Why Is regulation of MyD88-independent toll-like receptor signaling pathway Important in Cell Biology?
The MyD88-independent TLR pathway is a principal source of type-I interferon during infection, and its regulators determine the magnitude and duration of antiviral and antibacterial responses [1,2]. Because excessive or insufficient activity of this branch contributes to immunopathology and impaired pathogen clearance, identifying its positive and negative regulators is a major goal in innate immunity research [3,6,7].
• Controls IRF3/IRF7-dependent type-I interferon production downstream of TLR3 and TLR4 [1,2].
• Essential for host defense against intracellular bacteria such as Burkholderia pseudomallei.
• Modulates endothelial inflammatory responses to lipopolysaccharide.
• Required for TLR-stimulated phagocytosis through an actin-Cdc42/Rac pathway.
• Evolutionarily conserved across metazoans, enabling comparative studies.
• Targeted by negative regulators such as SIRPA and microRNA-7/FAM177A [3,7].
• Relevant to vaccine adjuvant design and host-directed anti-infective therapy [1,6].
• Provides a tractable system for CRISPR functional genomics of innate immunity [1,6].
What Happens During regulation of MyD88-independent toll-like receptor signaling pathway?
Adaptor selection at the TLR TIR domain
In simple terms: The cell decides whether a TLR will use the MyD88 route or the TRIF/TRAM route.
Regulation begins at the receptor level, where TRAM (TICAM2) facilitates recruitment of TRIF (TICAM1) to TLR4, and TRIF is directly recruited by TLR3, thereby initiating the MyD88-independent branch [1,6]. Regulators that alter TRAM/TRIF availability or TIR-domain interactions therefore modulate the pathway at its earliest step.
TRIF-dependent activation of IRF3 and IRF7
In simple terms: TRIF sets off a chain that switches on interferon-producing transcription factors.
Once engaged, TRIF nucleates a signaling complex that activates TBK1/IKKepsilon and subsequently IRF3, while IRF-7 acts as the master regulator of type-I interferon-dependent immune responses [1,2]. Regulators of this step control the amplitude of interferon gene transcription.
Late NF-kB activation
In simple terms: The pathway also turns on a slower wave of inflammatory gene expression.
In addition to IRF activation, TRIF signaling drives delayed NF-kB activation, which is distinct from the rapid MyD88-dependent NF-kB wave. Regulators that selectively affect this late phase shape the inflammatory output of TLR engagement [1,6].
Negative regulation by SIRPA and microRNA-7/FAM177A
In simple terms: Brakes exist to prevent the pathway from running too long.
Signal regulatory protein alpha (SIRPA) impairs the MyD88-independent pathway and reduces intracellular killing of Burkholderia pseudomallei in mouse macrophages. Separately, microRNA-7 negatively regulates TLR4 signaling through FAM177A, illustrating post-transcriptional control of this branch.
Crosstalk with phagocytosis and actin remodeling
In simple terms: The pathway also controls the cell's skeleton to help it engulf microbes.
MyD88-independent activation of a novel actin-Cdc42/Rac pathway is required for TLR-stimulated phagocytosis, showing that regulators of this branch also influence cytoskeletal dynamics. This connects GO:0034127 to cell biological outputs beyond transcription.
Evolutionary conservation of the regulatory logic
In simple terms: The same regulatory design appears across many animal species.
Phylogenetic analysis of TLR signaling has shown that the MyD88-independent branch and its regulatory components are conserved and adaptable across metazoans. This conservation supports the use of diverse model systems to study GO:0034127.
Key Genes Involved in GO:0034127 regulation of MyD88-independent toll-like receptor signaling pathway
The following genes and proteins are experimentally implicated in the regulation or execution of the MyD88-independent TLR signaling pathway.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TRIF (TICAM1) | Core adaptor of the MyD88-independent pathway | Essential for IRF3 activation and interferon induction |
| TRAM (TICAM2) | Bridging adaptor for TLR4 MyD88-independent signaling | Required for TRIF recruitment to TLR4 |
| IRF3 | Transcription factor activated downstream of TRIF | Drives type-I interferon gene expression |
| IRF7 | Master regulator of type-I interferon-dependent responses | Amplifies interferon production |
| SIRPA | Negative regulator of TLR signaling | Impairs MyD88-independent pathway and bacterial killing |
| FAM177A | Effector of microRNA-7-mediated TLR4 regulation | Post-transcriptional brake on TLR4 signaling |
| MIR7 | MicroRNA that negatively regulates TLR4 signaling | Modulates MyD88-independent branch via FAM177A |
| CDC42 | Small GTPase in actin remodeling | Required for TLR-stimulated phagocytosis |
| RAC1 | Small GTPase in actin remodeling | Required for TLR-stimulated phagocytosis |
| TBK1 | Kinase activating IRF3/IRF7 | Central node in TRIF-dependent signaling |
| IKBKE | Kinase cooperating with TBK1 | Contributes to IRF activation |
| NFKB1 | Transcription factor for late NF-kB response | Mediates delayed inflammatory gene expression |
| TLR3 | Receptor that signals exclusively via TRIF | Model receptor for MyD88-independent pathway |
| TLR4 | Receptor using both MyD88 and TRIF/TRAM | Key receptor for LPS-induced MyD88-independent signaling [6,8] |
| TRAF3 | Signaling intermediate downstream of TRIF | Scaffold for TBK1/IKKepsilon activation |
| TRAF6 | Signaling intermediate contributing to NF-kB | Supports late NF-kB activation |
| STAT1 | Interferon-responsive transcription factor | Readout of type-I interferon output |
How Is regulation of MyD88-independent toll-like receptor signaling pathway Regulated?
Regulation of the MyD88-independent TLR pathway occurs at multiple levels. At the receptor-proximal level, TRAM availability and TIR-domain interactions determine whether TRIF is recruited. Downstream, kinases such as TBK1 and IKKepsilon control IRF3/IRF7 activation, and IRF-7 itself acts as the master regulator of type-I interferon-dependent immune responses, creating a positive feedback loop [1,2]. Negative regulation is exerted by SIRPA, which impairs the MyD88-independent pathway and intracellular killing of Burkholderia pseudomallei, and by microRNA-7 through FAM177A, which dampens TLR4 signaling. In endothelial cells, lipopolysaccharide signaling is similarly subject to tight regulation, underscoring the cell-type specificity of these control mechanisms.
regulation of MyD88-independent toll-like receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SIRPA | Impaired killing of Burkholderia pseudomallei | Macrophage KO and overexpression |
| TRIF (TICAM1) | Defective antiviral interferon responses | TLR3/TLR4-stimulated KO cells |
| IRF7 | Impaired type-I interferon immunity | Knockout and knock-in reporter models |
| FAM177A | Dysregulated TLR4 inflammatory signaling | microRNA-7 mimic/inhibitor studies |
| CDC42 | Defective TLR-stimulated phagocytosis | Actin-remodeling assays in KO cells |
Infectious disease and intracellular bacterial killing
SIRPA-mediated impairment of the MyD88-independent pathway reduces intracellular killing of Burkholderia pseudomallei in mouse macrophages, linking regulators of GO:0034127 to melioidosis susceptibility. More broadly, TRIF-dependent interferon production is required for effective antiviral immunity downstream of TLR3 and TLR4 [1,2].
Inflammatory and endothelial disease
Lipopolysaccharide signaling in endothelial cells involves MyD88-independent components, and its dysregulation contributes to vascular inflammation. Regulators that tune this branch therefore influence inflammatory disease phenotypes [6,8].
Host-pathogen interactions and phagocytosis
MyD88-independent activation of actin-Cdc42/Rac signaling is required for TLR-stimulated phagocytosis, a process whose failure can compromise pathogen clearance. This positions GO:0034127 regulators as modifiers of host-pathogen outcomes [5,7].
From regulation of MyD88-independent toll-like receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for TRIF-dependent IRF3 activation? | CRISPR knockout in TLR3/TLR4-expressing cells |
| Does a point mutation in a regulator alter pathway output? | CRISPR point-mutation knock-in [1,6] |
| Where does a regulator localize during signaling? | Tagged knock-in with fluorescent tag |
| Does overexpression of a regulator dampen interferon induction? | Stable overexpression cell line |
| Which genes modify MyD88-independent signaling genome-wide? | CRISPR library screening [1,6] |
| Is a regulator conserved across species? | Comparative knockout in model organisms |
How to Study the regulation of MyD88-independent toll-like receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptional output | Interferon and inflammatory gene signatures [1,2] |
| qRT-PCR | Target gene expression | Validation of IRF3/IRF7 target genes |
| Co-immunoprecipitation | Protein-protein interactions | TRIF/TRAM complex assembly [1,6] |
| Phospho-immunoblot | Kinase activation status | TBK1/IRF3 phosphorylation |
| CRISPR knockout | Gene requirement | Loss-of-function pathway dissection [1,6] |
| CRISPR library screen | Genome-wide modifiers | Discovery of novel regulators [1,6] |
| Phagocytosis assay | Actin-dependent uptake | Host-pathogen interaction studies [5,7] |
| Phylogenetic analysis | Evolutionary conservation | Cross-species pathway comparison |
Transcriptional readouts of pathway activity
Quantitative RT-PCR and RNA-seq of interferon-stimulated genes and inflammatory cytokines are standard readouts for regulators of the MyD88-independent branch, since TRIF signaling drives IRF3/IRF7-dependent transcription [1,2].
Protein interaction and phosphorylation analysis
Co-immunoprecipitation and phospho-specific immunoblotting for TBK1, IRF3, and IRF7 are used to determine whether a regulator acts at the adaptor or kinase step of the pathway [1,6].
Functional phagocytosis and bacterial killing assays
Actin-remodeling and intracellular killing assays in macrophages allow researchers to test whether regulators of MyD88-independent signaling affect phagocytosis and pathogen clearance [5,7].
Comparative and phylogenetic analysis
Sequence and pathway-level phylogenetic comparisons across metazoans help identify conserved regulatory components of the MyD88-independent pathway.
How CRISPR Can Be Used to Study GO:0034127 regulation of MyD88-independent toll-like receptor signaling pathway
Knockout
CRISPR knockout of TRIF (TICAM1), TRAM (TICAM2), or candidate regulators is the most direct way to test necessity in the MyD88-independent pathway, since TRIF loss abolishes IRF3 activation downstream of TLR3 and TLR4 [1,6].
Point Mutation
Point-mutation knock-in can be used to disrupt specific phospho-acceptor sites or interaction residues in regulators such as IRF7 or TBK1, allowing separation of pathway branches without deleting the entire protein [1,2].
Knock-in
Tagged knock-in of TRIF, TRAM, or IRF7 enables live-cell imaging and proteomic mapping of the MyD88-independent signaling complex in its native genomic context [1,6].
Overexpression
Overexpression of negative regulators such as SIRPA or FAM177A can be used to test whether increased dosage dampens MyD88-independent signaling and bacterial killing [3,7].
How EDITGENE Supports regulation of MyD88-independent toll-like receptor signaling pathway Research
Researchers studying regulation of MyD88-independent toll-like receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in TRIF/TRAM-dependent signaling or is merely correlated with pathway activity. EDITGENE provides the CRISPR cell models and screening services required to move from correlation to causation in this pathway.
Contact EDITGENE today to design your custom CRISPR model for regulation of MyD88-independent toll-like receptor signaling pathway research.
Frequently Asked Questions About regulation of MyD88-independent toll-like receptor signaling pathway
What is GO:0034127?
GO:0034127 is the Gene Ontology biological_process term for any process that modulates the frequency, rate, or extent of the MyD88-independent toll-like receptor signaling pathway, the TRIF/TRAM-dependent branch of TLR signaling [1,6].
What is the MyD88-independent toll-like receptor signaling pathway?
It is the branch of TLR signaling that does not use the adaptor MyD88 and instead depends on TRIF and TRAM to activate IRF3/IRF7 and late NF-kB, leading to type-I interferon production [1,6].
What genes are involved in regulation of MyD88-independent toll-like receptor signaling pathway?
Key genes include TRIF (TICAM1), TRAM (TICAM2), IRF3, IRF7, TBK1, IKBKE, SIRPA, FAM177A, and MIR7, among others [1,2,3,6,7].
Which TLRs use the MyD88-independent pathway?
TLR3 signals exclusively through TRIF, while TLR4 uses both MyD88-dependent and TRIF/TRAM-dependent branches [1,6].
How is the MyD88-independent pathway negatively regulated?
Negative regulation occurs through proteins such as SIRPA, which impairs the pathway and bacterial killing, and through microRNA-7 acting via FAM177A to dampen TLR4 signaling [3,7].
What is the role of IRF7 in this pathway?
IRF-7 is the master regulator of type-I interferon-dependent immune responses and is a central transcription factor downstream of TRIF signaling.
Why is the MyD88-independent pathway important for bacterial killing?
It supports intracellular killing of pathogens such as Burkholderia pseudomallei, and its impairment by SIRPA reduces bacterial clearance in macrophages.
Does the MyD88-independent pathway affect phagocytosis?
Yes, MyD88-independent activation of an actin-Cdc42/Rac pathway is required for TLR-stimulated phagocytosis.
Is the MyD88-independent pathway conserved in evolution?
Phylogenetic studies show that TLR signaling, including MyD88-independent components, is conserved and adaptable across metazoans.
How can I study regulators of GO:0034127 experimentally?
CRISPR knockout, point-mutation, knock-in, and overexpression models combined with RNA-seq, phospho-immunoblotting, and phagocytosis assays are standard approaches [1,5,6,7].
Conclusion
GO:0034127 captures the regulatory layer that tunes the TRIF/TRAM-dependent branch of TLR signaling, a pathway essential for type-I interferon production, late NF-kB activation, and host defense against intracellular pathogens [1,2,6,7]. Its key nodes, including TRIF, TRAM, IRF3, IRF7, SIRPA, and the microRNA-7/FAM177A axis, are experimentally tractable and conserved across species [3,4,7]. Because dysregulation of this pathway contributes to impaired pathogen clearance and inflammatory pathology, precise CRISPR models are needed to establish causality for candidate regulators [1,5,6,7]. EDITGENE provides the knockout, point-mutation, knock-in, overexpression, and screening platforms required to dissect GO:0034127 in any cell type of interest.
References
- 1. Yamamoto M et al.. 2003. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway.. Science 301(5633):640-3 PMID: 12855817
- 2. Honda K et al.. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses.. Nature 434(7034):772-7 PMID: 15800576
- 3. Chen H et al.. 2021. MicroRNA-7 negatively regulates Toll-like receptor 4 signaling pathway through FAM177A.. Immunology 162(1):44-57 PMID: 32852789
- 4. Roach JM et al.. 2013. Phylogeny of Toll-like receptor signaling: adapting the innate response.. PLoS One 8(1):e54156 PMID: 23326591
- 5. Kong L et al.. 2008. MyD88-independent activation of a novel actin-Cdc42/Rac pathway is required for Toll-like receptor-stimulated phagocytosis.. Cell Res 18(7):745-55 PMID: 18542102
- 6. Lannoy V et al.. 2023. TIRAP, TRAM, and Toll-Like Receptors: The Untold Story.. Mediators Inflamm 2023:2899271 PMID: 36926280
- 7. Baral P et al.. 2012. Involvement of signal regulatory protein α, a negative regulator of Toll-like receptor signaling, in impairing the MyD88-independent pathway and intracellular killing of Burkholderia pseudomallei-infected mouse macrophages.. Infect Immun 80(12):4223-31 PMID: 22988019
- 8. Dauphinee SM et al.. 2006. Lipopolysaccharide signaling in endothelial cells.. Lab Invest 86(1):9-22 PMID: 16357866
